Ruxolitinib in the Treatment of Polycythemia Vera: Patient Selection and Special Considerations

In a meta-analysis, researchers concluded that ruxolitinib’s place in current practice should be directed toward disease-related symptoms relief after failure of standard treatment.

 Journal of Blood Medicine

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.